Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Eton Pharmaceuticals, Inc. (ETON)

Eton Pharmaceuticals' ET-700 pilot shows fewer side effects than GALZIN but weaker copper effect

Mixed Impact 3 of 5 other Written later

Eton Pharmaceuticals reported preliminary results from a four-week, placebo-controlled pilot study of ET-700, its investigational zinc acetate formulation for Wilson disease, in healthy volunteers. ET-700 showed fewer treatment-related adverse events than GALZIN but reduced hepatic copper uptake by less (12% versus 46%), and the company plans additional study arms in 2027. The filing states the findings are preliminary and do not establish clinical efficacy in patients with Wilson disease.

Key points

  • Treatment-related adverse events: 1 of 12 ET-700 participants versus 8 of 12 GALZIN participants
  • Hepatic copper uptake decreased 12% with ET-700 and 46% with GALZIN; placebo rose 11%
  • Intention-to-treat analysis of 35 participants showed GALZIN had a greater effect than ET-700 (p=0.023)
  • Company plans additional study arms in 2027 evaluating faster-release formulations

The filing

CompanyEton Pharmaceuticals, Inc. (ETON)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:03 PM ET
Accession number0001437749-26-035258

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.